Missed Allergy Shot: Dose Adjustment Protocols by Gap Duration

Missing a single allergy shot is not catastrophic, but the dose adjustment required depends on how long the gap is. During build-up, a gap of less than 2 weeks allows normal dose progression at the next visit. A gap of 2-3 weeks requires repeating the last tolerated dose rather than advancing. During maintenance, a gap of less than 5 weeks allows continuation at the same maintenance dose without adjustment. The reason adjustments are needed at all is that the desensitized state built through consistent allergen exposure begins to fade without regular reinforcement. Tolerance decay increases the risk that the immune system will react more strongly upon dose resumption. When in doubt, contact your allergist's clinic before the next appointment to confirm the correct dose.

Whether you need to restart from the beginning depends entirely on how long the gap was. During the build-up phase, only a gap of 90 or more days requires restarting from the first dilution vial. Shorter gaps require dose reductions proportional to the gap length, not a full restart. During maintenance, a gap of 3-4 months or more (typically defined as 13-16 weeks) requires restarting the full protocol. For gaps shorter than these thresholds, resuming at a reduced dose — without a full restart — is appropriate. The key principle is that even when a restart is required, patients often re-escalate faster the second time because some immunological memory persists.

The question of how many shots you can miss before needing to restart depends on the cumulative gap duration, not the number of missed visits per se. During build-up, a gap reaching 90 days requires restarting from vial 1 regardless of how many individual injections were missed. During maintenance, a gap of 3-4 months (13-16 weeks) typically requires a full restart. Between those extremes, progressive dose reductions allow safe resumption without restarting: a 2-3 week build-up gap means repeating the last dose; a 5-7 week maintenance gap means a 25% reduction. The practical implication is that occasional missed appointments are manageable, but extended multi-week absences — common due to travel, illness, or scheduling difficulties — require progressively larger dose reductions.

Missing allergy shots temporarily increases the risk of a systemic reaction when you resume. This occurs because the desensitized state fades without regular antigen exposure. When you then receive a dose that was previously tolerated, your immune system may react more strongly than it would have if treatment had been uninterrupted. This is why dose reductions after gaps are not optional — they are a safety measure, not just a conservative preference. The danger is real but manageable when proper dose adjustment protocols are followed. The greater long-term danger of missed appointments is efficacy loss: inconsistent dosing prevents the immune system from completing the remodeling that produces durable post-treatment benefit, undermining the entire treatment investment.

Stopping allergy shots for a few months (3-4 months or more during maintenance) typically requires restarting the full treatment protocol from the beginning. This is because the tolerance established over months of consistent maintenance dosing decays significantly over this period. The AAAAI/ACAAI Practice Parameter identifies a maintenance gap of approximately 13-16 weeks as the threshold for requiring a restart. Starting over is frustrating but is the safest approach — attempting to resume at the previous high maintenance dose after extended tolerance decay creates substantial systemic reaction risk. If you are considering stopping for an extended period, discussing a planned pause with your allergist before stopping allows proper protocol planning and potentially a scheduled re-start with appropriate dose reduction.

The desensitized state maintained by regular allergy shots depends on ongoing allergen-specific immune regulation. Regular subcutaneous allergen exposure sustains the populations of FOXP3+ regulatory T cells (Tregs) and IL-10-producing regulatory B cells that suppress the IgE-mediated allergic response. When allergen exposure stops, these regulatory cell populations gradually contract, allergen-specific IgG4 blocking antibody levels begin to fall, and the inhibitory state weakens. Simultaneously, the mast cells and basophils that were functionally desensitized regain sensitivity over weeks without allergen. The result is that a dose that was previously well tolerated becomes capable of triggering a more significant immune response. This is why the missed-dose adjustment protocols exist — they allow safe re-entry at a level the recovering tolerance can handle.